+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 0 - 50Years
All Genders
ID06302270

Study of Women With Cystic Fibrosis Using Elexacaftor-tezacaftor-ivacaftor During Pregnancy and Breastfeeding and Their Children

Led by Region Stockholm · Updated on 2024-03-08

75

Participants Needed

1

Research Sites

260 weeks

Total Duration

AI-Summary

What This Trial Is About

This observational study focuses on women with cystic fibrosis who are treated with CFTR modulators during pregnancy and postpartum, along with their children. The research aims to monitor maternal health and investigate the effects of CFTR modulators on newborn infants, including exposure through the mothers own milk. The study is sponsored by Region Stockholm and seeks to provide important insights regarding this specific population. Participants include mother-infant pairs where the mother has cystic fibrosis and is receiving treatment with the combination drug Kaftrio. The study follows these pairs over time without administering new treatments, observing natural outcomes related to exposure during pregnancy and breastfeeding. During the study, researchers will collect health information about the newborn infants and mothers, tracking health effects in the infants up to six years of age. No experimental treatments are given, and the study will last until 2039. Participants can expect regular health assessments and monitoring to understand the long-term impact of the medication exposure.

CONDITIONS

Brief Title

CFTR Modulators in Pregnancy and Postpartum

Research Team

J

jenny svedenkrans

T

Terezia Pinzikova

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here